Results 41 to 50 of about 688 (142)

Exposure the Hazardous Potential of Quinalphos: An In-Depth Analysis for Environmental and Biological Effects on Human Health. [PDF]

IET Syst Biol
This study elucidates pesticide docking onto proteins encoded by differentially expressed genes, revealing interaction networks involving chemicals, genes, proteins, drugs and diseases. It highlights structural insights, regulatory pathways and potential therapeutic or environmental implications, providing a comprehensive understanding of the ...
Choudhari JK, Sahariah BP, Jayapal AK, Choubey J, Tripathi A.   +4 more
europepmc   +2 more sources

Ospemifene plus fractional CO2 laser: a powerful strategy to treat postmenopausal vulvar pain [PDF]

, 2020
This study is a single-center, retrospective analysis of postmenopausal women presenting with dyspareunia and vulvar pain, aiming to evaluate relative effectiveness of vestibular CO2 laser therapy as a treatment.
Nelvastellio L., Felice R., Di Francesco S., Murina F., Cetin I.   +4 more
core   +1 more source

Recent advances in managing overactive bladder [version 1; peer review: 3 approved]

F1000Research, 2020
Overactive bladder syndrome (OAB) is defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology. In this review, we focus on recent
George Araklitis, Georgina Baines, Ana Sofia da Silva, Dudley Robinson, Linda Cardozo   +4 more
doaj   +1 more source

A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system

, 2023
Ospemifene has been authorized for the treatment of vulvovaginal atrophy (VVA). This study wasto evaluate adverse events (AEs) associated with ospemifene by data mining the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Meng Zhang (154027), Haixiao Wen (16880871), Xingling Qi (10802783), Chong Lu (1868521)   +3 more
core   +1 more source

No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA) [PDF]

, 2020
Objective: To estimate the incidence and recurrence of breast cancer (BC) in patients with vulvovaginal atrophy (VVA) treated with ospemifene and matched untreated VVA patients using real-world data.
Villa, P., Particco, M, Djumaeva, S, Villa, P, Altomare, C, Biglia, N, Cai, B, Paola Villa, Panay, N, Biglia, N., Simon, James, Kanakamedala, H   +11 more
core   +1 more source

Ospemifene in the Treatment of Vulvovaginal Atrophy

, 2014
Objective: To review the pharmacology, efficacy, and safety of ospemifene in the management of dyspareunia. Data Sources: Literature was sought using PubMed (1966-January 2014) and EMBASE (1973-January 2014).
Forinash, Alicia B., Barnes, Kylie N., Pearce, Erica F., Yancey, Abigail M.   +3 more
core   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper

International Journal of Gynecology &Obstetrics, Volume 175, Issue 1, Page 26-47, October 2026.
Abstract Premature ovarian insufficiency (POI) and early menopause (EM) affect millions of women worldwide. Compared with normal menopause, they confer a longer duration of estrogen deficiency and are associated not only with a shorter lifespan, but with a reduced healthspan, owing to an increased risk of cardiovascular, skeletal, cognitive and ...
Chiara Benedetto, Suvarna S. Khadilkar, Rossella E. Nappi, Andrea R. Genazzani, Federica Frezet, Laura Cucinella, Hema Divakar, Panagiotis Anagnostis, Nick Panay   +8 more
wiley   +1 more source

Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women [PDF]

, 2014
Objective To examine the long-term safety of oral ospemifene, a non-estrogen tissue-selective estrogen agonist/antagonist, for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
The Ospemifene Study Group, Simon, James A., Mabey, R. Garn, Portman, David J.   +3 more
core  

Effect of ospemifene on vaginal microbiome in postmenopausal women with vulvovaginal atrophy

, 2023
Objectives: This study aimed (i) to compare the vaginal microbiome profiles of women suffering from vulvovaginal atrophy with that of healthy postmenopausal women and to (ii) assess the effect of ospemifene and systemic hormone treatment on the ...
Camilla Ceccarani, Alessandra Lami, Meriggiola, Maria Cristina, Marco Severgnini, Baldassarre, Maurizio, Ceccarani, Camilla, Renato Seracchioli, Consolandi, Clarissa, Tania Camboni, Seracchioli, Renato, Claudio Foschi, Camboni, Tania, Stefania Alvisi, Alvisi, Stefania, Foschi, Claudio, Clarissa Consolandi, Lami, Alessandra, Maurizio Baldassarre, Severgnini, Marco, Maria Cristina Meriggiola   +19 more
core   +1 more source